Back to results
US 12,275,986 B2Granted
Biomarkers associated with checkpoint immune therapy and methods of using same
AssigneeDuke University
InventorsChuan-Yuan Li, Dong Pan
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating cancer in a subject comprising administering an ICB therapy to a subject having cancer, wherein the subject's cancer comprises one or more mutations in two or more genes associated with responsiveness to immune checkpoint blockade (ICB).
Claims13
A method for treating cancer in a subject comprising:
- (a) detecting the presence or absence of a mutation in each of a plurality of genes associated with responsiveness to immune checkpoint blockade (ICB) therapy, in a biological sample from a subject having non-small cell lung cancer (NSCLC),
- wherein the plurality of genes associated with responsiveness to ICB therapy consists of the genes:
- ABLI, ASXLI, ATM, BCOR, BRCA2, BRIP1, CARD11, CD79B, CDC73, CIC, EPHA3, EPHAS, EPHA, EPHB1, ERBB4, ERCC4, FGFR4, FLT3, FOXL2, HGF, INHBA, JAK3, MAX, MDC1, MED12, MET, MGA, MRE11, MSH2 NF2, NFKBIA, NOTCH1, NOTCH2, NTRK3, NUF, PARP], PAX5, PGR, PIK3C2G, PIK3C3, PIK3CG, PIM1, POLE, PPMID, PPP2RIA, PTPRD, RET, STAT3, TENT, TET1, TSC2, and ZFHX3;
- and
- (b) administering an ICB therapy to the subject having cancer when the subject has mutations in two or more of the plurality of genes associated with responsiveness to ICB therapy.
2 more elements
Dependencies are inferred from the claim text.